Update on mesalazine for inflammatory bowel disease

Keyphrases

• Inflammatory Bowel Disease 100%
• Mesalazine 100%
• Moderate to Severe 13%
• Remission 13%
• Dose-response 13%
• Crohn's Disease 13%
• Moderate Disease 13%
• Quality of Life 6%
• Europe 6%
• Surgical Resection 6%
• North America 6%
• Number of Patients 6%
• Ulcerative Colitis 6%
• Long-term Adverse Effects 6%
• Active Therapy 6%
• Oral Dose 6%
• First-line Therapy 6%
• Remission Induction 6%
• Non-smokers 6%
• Placebo Response 6%
• Topical Therapy 6%
• Safety Margin 6%
• Active Ulcerative Colitis 6%
• Oral Therapy 6%
• Distal Colitis 6%
• Maintenance Therapy 6%
• Maintenance Dose 6%
• Optimal Maintenance 6%
• Large Margin 6%
• Ileocolonic Anastomosis 6%
• Maintenance Approaches 6%

Medicine and Dentistry

• Inflammatory Bowel Disease 100%
• Mesalazine 100%
• Ulcerative Colitis 20%
• Crohn's Disease 13%
• Salazosulfapyridine 13%
• Dose Response 13%
• Diseases 13%
• Side Effect 6%
• Topical Treatment 6%
• Surgical Anastomosis 6%
• Maintenance Therapy 6%
• Maintenance Drug Dose 6%
• Quality of Life 6%
• Placebo Effect 6%